# PICO Table
([switch to Risk of Bias table](risk-of-bias.md))

## Randomized controlled trials
Study                                                           |Patients/population/problem|Intervention|Comparison|Outcome|
----------------------------------------------------------------|---------------------------|------------|----------|-------|
|Mathieson (PRECISE)<br>2017<br>PMID [28328324](http://pubmed.gov/28328324)<br>[ACTRN12613000530729](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364108) |Adults with sciatica for at least one week.<br> • Duration of leg pain: 2 months average| Pregabalin up to 300 mg twice daily | Placebo |At 8 weeks:<br> • 0 to 10 Numeric rating scale (NRS) for leg pain<br>• Roland Disability Questionnaire for Sciatica|
|Atkinson<br>2016<br>PMID [26963844](http://pubmed.gov/26963844)<br>[NCT00108550](http://clinicaltrials.gov/show/NCT00108550)|Adults with nonspecific lumbar pain for 6 months or more.<br>• Duration of symptoms: 17 years average<br>• Subgrouped by pain with radiating pain. | Gabapentin up to 1200 mg three times a day| Placebo|At 12 weeks:<br>•  Descriptor Differential Scale (DDS)<br>• 0 to 10 Numeric rating scale (NRS)<br>• Oswestry Disability Index (ODI)|
|Kim<br>2016<br>PMID [27045252](http://pubmed.gov/27045252)<br>[NCT01888536](http://clinicaltrials.gov/show/NCT01888536)|Adults with lumbar spinal stenosis.<br>• All patients were taking limaprost as part of a crossover trial.<br> • Duration of symptoms: 7 months average  | Pregabalin 75 mg three times a day| Placebo|At 8 weeks:<br>•  Descriptor Differential Scale (DDS)<br>• 0 to 10 Numeric rating scale (NRS)<br>• Oswestry Disability Index (ODI)<br>• Leg pain measured by visual analogue scale (VAS)<br>• Other outcomes|
| NCT01838044 <br>2016<br>[NCT01838044](https://clinicaltrials.gov/show/NCT01838044) |Adults with chronic low back pain and "high probability of a significant neuropathic component "<br> • All patients were taking celecoxib<br> • Duration of symptoms: 3 months to 4 years| Pregabalin up to 300 mg daily |Placebo|At 5 and 10 weeks:<br>• 0 to 10 Numeric rating scale (NRS)<br>• Others|
|Markman<br>2015<br>PMID [25503625](http://pubmed.gov/25503625)<br>[NCT00638443](http://clinicaltrials.gov/show/NCT00638443)|Adults with neurogenic claudication.<br>• Cross-over trial with 7 day washout between periods.<br>• Duration of symptoms: > 3 months with most > one year.  | Pregabalin 150 mg twice day| Placebo|At 10 days:<br>•  Descriptor Differential Scale (DDS)<br>• 0 to 10 Numeric rating scale (NRS)<br>• Oswestry Disability Index (ODI)<br>• Other outcomes|
| Baron (A0081007 Investigators)<br>2010<br>PMID [20493632](http://pubmed.gov/20493632) |Adults with chronic lumbosacral radiculopathy due to spinal stenosis or disk herniation for at least 3 months.<br>•  Subjects must have responded to run in pregabalin but not to placebo<br> • Duration of symptoms: not reported | Pregabalin up to 600 mg daily|Placebo|At six weeks:<br>• 0 to 10 Numeric rating scale (NRS)<br>• Time to loss of response (LOR)<br>• Others|
| Yildirim <br>2003<br>DOI [10.1163/156856903767650718](http://dx.doi.org/10.1163/156856903767650718) |Adults with chronic lumbosacral radiculopathy due to disk bulging or protrusion<br> • Duration of symptoms: 67 months average<br>•  Excluded patients intolerant of gabapentin| Gabapentin up to 1200 mg three times daily |Placebo|At eight weeks:<br>• 0 to 3 Numeric rating scale (NRS)
| McCleane <br>2001<br>DOI [10.1163/156856901753420945](http://dx.doi.org/10.1163/156856901753420945) |Adults with low back pain and associated referred leg pain<br> • Duration of symptoms: pending full text| Gabapentin up to 1200 mg dailypentin |Placebo|At eight weeks:<br>• 0 to 10 Numeric rating scale (NRS)<br>• Others|

**Footnotes:**<br>
*
†

